Heart failure & cardiomyopathiesSecondary analysis
Empagliflozin and Risk of Lower Respiratory Tract Infection in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: An EMPEROR-Preserved Analysis
- Secondary analysis of the EMPEROR-Preserved randomised trial
- time-updated models
- Cox regression
Authors' conclusion
In EMPEROR-Preserved, LRTI was frequent and associated with a poor prognosis. Empagliflozin was associated with a reduced risk of LRTI compared to placebo.
Study context
- Population
- Patients with HF with mildly reduced or preserved EF (HFmrEF/HFpEF) in EMPEROR-Preserved
- Participants
- 5,988 patients
- Comparison
- Empagliflozin vs placebo
- Primary endpoint
- Incident lower respiratory tract infection (LRTI)
- Follow-up
- Median 26 months
Primary result
Incident LRTI
Hazard ratio
0.83
95% CI 0.71–0.96
P = 0.014
By group
Empagliflozin vs Placebo
HR 0.83 (95% CI 0.71–0.96); P = 0.014
As reported in the abstract
Further findings
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| Total LRTI events | 0.80 (0.68–0.94) | P = 0.008 | |
| 0.512Incidence rate ratio (log scale) |
Lower respiratory tract infections (LRTI) frequency and prognosis
- Patients developing LRTI
- 699 of 5988 (11.7%)
- Risk of subsequent mortality after LRTI vs no LRTI
- 2.7-fold higher
COVID-19 incidence
- No effect of empagliflozin on COVID-19 incidence
Original publication
Empagliflozin and Risk of Lower Respiratory Tract Infection in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: An EMPEROR-Preserved Analysis. Eur J Heart Fail. Published 4 March 2024. doi:10.1002/ejhf.3180
Summarised from the published abstract; every number is checked against it